Lallas Konstantinos (@lallaskon) 's Twitter Profile
Lallas Konstantinos

@lallaskon

MD, MSc, PhDc, Oncology Resident, Papageorgiou Hospital, Medical Research Methodology, Skin cancer, Melanoma § SKG, Greece

ID: 3261097351

calendar_today30-06-2015 08:39:08

25 Tweet

68 Followers

301 Following

Lallas Konstantinos (@lallaskon) 's Twitter Profile Photo

What an important discussion!! Listening to residents’ problems and trying to solve with!! #medicalassociation #Thessaloniki #residents #ΙΣΘ

What an important discussion!! Listening to residents’ problems and trying to solve with!! #medicalassociation #Thessaloniki #residents #ΙΣΘ
U.S. FDA (@us_fda) 's Twitter Profile Photo

Today, we approved the first cellular therapy indicated for treatment of adult patients with a type of skin cancer that is unable to be removed with surgery or has spread to other parts of the body that have previously been treated with other therapies. fda.gov/news-events/pr…

Today, we approved the first cellular therapy indicated for treatment of adult patients with a type of skin cancer that is unable to be removed with surgery or has spread to other parts of the body that have previously been treated with other therapies. fda.gov/news-events/pr…
Ιατρικός Σύλλογος Θεσσαλονίκης (@isthgr) 's Twitter Profile Photo

Εκδήλωση για την Πανευρωπαϊκή Ημέρα Ευαισθητοποίησης κατά της Βίας σε γιατρούς και υγειονομικούς isth.gr/ekdilosi-gia-t… Aπευθείας μετάδοση ΑΥΡΙΟ στις 13.30 από το νοσοκομείο "Παπαγεωργίου" #Θεσσαλονικη

Lallas Konstantinos (@lallaskon) 's Twitter Profile Photo

Great discussion with med. students about mentorship programs, research and educational opportunities after graduation!! Audience full of energy and questions and great speakers Andreas Kyriakou!!

Great discussion with med. students about mentorship programs, research and educational opportunities after graduation!! Audience full of energy and questions and great speakers <a href="/andreaskyr93/">Andreas Kyriakou</a>!!
Lallas Konstantinos (@lallaskon) 's Twitter Profile Photo

Totally fresh and promising biomarker of #Melanoma! In our study at #ASCO24, a ML algorithm, using dermatoscopy, predicted metastasis with great accuracy before excision! Let’s see the effect on patients’ risk stratification and treatment selection! ascopubs.org/doi/10.1200/JC…

NEJM (@nejm) 's Twitter Profile Photo

Presented at #ASCO24: Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: nej.md/3wSo3uk

Presented at #ASCO24: 

Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: nej.md/3wSo3uk
Lallas Konstantinos (@lallaskon) 's Twitter Profile Photo

A week full of innovative ideas, clinical trials and fruitful discussions with colleagues and an inspiring faculty Teresa Amaral, MD, PhD Victor Moreno Elisabeth de Vries - PDG9!! Amazing experience!! Highly recommended for young investigators!! #MCCR24 #melanoma #clinicaltrials

A week full of innovative ideas, clinical trials and fruitful discussions with colleagues and an inspiring faculty <a href="/TeresaSAmaral/">Teresa Amaral, MD, PhD</a> <a href="/VicMorenoGarcia/">Victor Moreno</a> <a href="/VriesElisabeth/">Elisabeth de Vries</a> - PDG9!! Amazing experience!! Highly recommended for young investigators!! 
#MCCR24 #melanoma #clinicaltrials
Lallas Konstantinos (@lallaskon) 's Twitter Profile Photo

Out in Critical Reviews in Oncology Hematology (CROH) our meta-analysis provides an overview of the prognostic factors of #melanoma and their role on distant metastasis development!! sciencedirect.com/science/articl…

Out in <a href="/CHematology/">Critical Reviews in Oncology Hematology (CROH)</a> our meta-analysis provides an overview of the prognostic factors of #melanoma and their role on distant metastasis development!! 

sciencedirect.com/science/articl…
ESMO - Eur. Oncology (@myesmo) 's Twitter Profile Photo

#ESMO24: Questions remain on optimal #AdjuvantTherapy for advanced #melanoma. OS trial data are not yet available & #RealWorld data suggest that surrogate endpoints may not translate into OS benefit in clinical practice Teresa Amaral, MD, PhD #ESMODailyReporter 📌ow.ly/51Cs50TnILV

#ESMO24: Questions remain on optimal #AdjuvantTherapy for advanced #melanoma. OS trial data are not yet available &amp; #RealWorld data suggest that surrogate endpoints may not translate into OS benefit in clinical practice <a href="/TeresaSAmaral/">Teresa Amaral, MD, PhD</a> #ESMODailyReporter
📌ow.ly/51Cs50TnILV
Lallas Konstantinos (@lallaskon) 's Twitter Profile Photo

Words cannot describe my gratitude for Teresa Amaral, MD, PhD ! An inspiring, supportive mentor and true leader! One year full of discussions and brainstorming! Amazing experience thanks to ESMO - Eur. Oncology and #mentorship program! Highly recommended for young oncologists! #ESMO24 #ESMOYOC

Words cannot describe my gratitude for <a href="/TeresaSAmaral/">Teresa Amaral, MD, PhD</a> ! An inspiring, supportive mentor and true leader! One year full of discussions and brainstorming! Amazing experience thanks to <a href="/myESMO/">ESMO - Eur. Oncology</a> and #mentorship program! Highly recommended for young oncologists!
#ESMO24 #ESMOYOC
Medicina MDPI (@mdpimedicina) 's Twitter Profile Photo

#mdpiMedicina #TopCitedPaper 📢Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma Subtypes ✍️By Elisa Camela et al. 👉mdpi.com/1648-9144/59/2… #SkinNeoplasms

#mdpiMedicina #TopCitedPaper 

📢Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma Subtypes

✍️By Elisa Camela et al.             
👉mdpi.com/1648-9144/59/2…

#SkinNeoplasms
Camille Cao (@camille43253543) 's Twitter Profile Photo

✨Call for papers! 📝Special Issue: Advances in the Diagnosis and Treatment of Skin Cancer  👨‍🎓Guest Editors: Dr. Konstantinos Lallas and Dr. Aimilios Lallas. Lallas Konstantinos Aimilios Lallas 🔗 Link: mdpi.com/si/226355 ⏲️ Deadline: 31 Oct 2025 JCM MDPI #SkinCancer #melanoma

✨Call for papers!
📝Special Issue: Advances in the Diagnosis and Treatment of Skin Cancer 
👨‍🎓Guest Editors: Dr. Konstantinos Lallas and Dr. Aimilios Lallas. <a href="/LallasKon/">Lallas Konstantinos</a>  <a href="/aimlallas/">Aimilios Lallas</a> 
🔗 Link: mdpi.com/si/226355
⏲️ Deadline: 31 Oct 2025

<a href="/JCM_MDPI/">JCM MDPI</a> 

#SkinCancer
#melanoma
Lallas Konstantinos (@lallaskon) 's Twitter Profile Photo

There is still time to register for #ESMOAcademy25!! An essential course for medical oncology residents and ESMO Examination participants! More info in the link: ow.ly/zUB050WnBQA #ESMOYOC #ESMOGRAmbassadors #OncResidents ESMO - Eur. Oncology

There is still time to register for #ESMOAcademy25!! An essential course for medical oncology residents and ESMO Examination participants!

More info in the link: ow.ly/zUB050WnBQA

#ESMOYOC #ESMOGRAmbassadors #OncResidents <a href="/myESMO/">ESMO - Eur. Oncology</a>